       Document 0514
 DOCN  M9640514
 TI    Willingness to participate in AIDS vaccine trials among high-risk
       populations in northern Thailand.
 DT    9604
 AU    Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo
       PO; Khamboonruang C; Nelson KE; School of Hygiene and Public Health,
       Johns Hopkins University,; Baltimore, Maryland 21205, USA.
 SO    AIDS. 1995 Sep;9(9):1079-83. Unique Identifier : AIDSLINE MED/96085725
 AB    OBJECTIVES: To determine the anticipated participation in a prophylactic
       AIDS vaccine trial and to identify perceived benefits and barriers to
       enrollment of HIV-seronegative volunteers at risk of HIV infection in
       northern Thailand. DESIGN: A cross-sectional survey. METHODS: Subjects
       interviewed in a cross-sectional survey included female commercial sex
       workers (n = 215), men attending sexually transmitted disease clinics (n
       = 219), conscripts in the Royal Thai Army (n = 1453), and men discharged
       from the army (n = 293) who had returned to civilian life. We determined
       AIDS vaccine knowledge and attitudes, perceived vulnerability to HIV
       infection, barriers and incentives to participate in a future vaccine
       trial and agreement to participate in a randomized trial. RESULTS:
       Awareness of vaccines (88-97%) and AIDS vaccine development efforts
       (62-77%) were common and viewed to be a complement to behavior change
       (74-94%). Approximately 25% of subjects would definitely join a trial if
       asked, and an additional 38% would accept an AIDS vaccine if they were
       convinced it would be safe and effective. Important barriers to
       participation included concerns with discrimination (16-45%), short-
       (37-60%) and long-term (30-55%) vaccine side-effects, fear of disability
       and death (36-58%), and beliefs that partners would refuse to have sex
       (24-49%) after immunization. The principal inducement to join a trial
       was health insurance (62%). CONCLUSION: Potential HIV vaccine trial
       participants have several fears of joining a vaccine study at this time.
       Information derived from Phase I/II trials is needed to address these
       concerns if enrollment in efficacy trials is to be successful in the
       near future.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION &
       CONTROL/TRANSMISSION  Adult  AIDS Vaccines/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/IMMUNOLOGY  *Clinical Trials  Cohort Studies
       Cross-Sectional Studies  Female  Human  Knowledge, Attitudes, Practice
       Male  Motivation  *Patient Acceptance of Health Care  Prostitution  Risk
       Factors  Support, Non-U.S. Gov't  Support, U.S. Gov't, Non-P.H.S.
       Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

